• Age 18 years old and older

• Cancer survivors with no evidence of disease (cancer);

• Completed neurotoxic chemotherapy, i.e., platinum agents, taxanes, vinca alkaloids, and bortezomib, at least three months before enrollment;

• A CIPN diagnosis based on symptom history, loss of deep tendon reflexes, or presence of symmetrical stocking-glove pain, numbness, or paresthesia;

• Answers yes to the following question: Do you feel as though your balance is affected from experiencing CIPN? or Are you afraid of falling as a result of your CIPN?;

• On a stable regimen (no change in past three months) if taking anti-neuropathy or other pain medications;

• Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤ 2

• Willing to adhere to all study-related procedures, including randomization to the Tai Chi or waitlist group, 2 in-person visits to Dana-Farber Cancer Institute (DFCI) (one within 2 weeks of enrollment and one at week 12);

• Willing to adhere to requirement that no new pain medication be taken throughout the study period; and

• Individuals receiving endocrine therapy or targeted/antibody therapy, such as trastuzumab, pertuzumab, or immunotherapy, will be eligible to participate.